Did you know?

20%

of individuals over the age of 50, and most over the age of 80, experience some difficulty swallowing (dysphagia)6

Elderly patients with swallowing difficulties may benefit from a formulation other than a solid oral dosage form7

  • Elderly patients with dysphagia may require a large number of prescriptions. Difficulties swallowing may limit administration of solid oral dosage forms7

  • Swallowing difficulties often lead to splitting, crushing, or opening tablets for elderly patients7

    • 58.8% of patients with dysphagia modify their drugs in a way that may alter safety and efficacy8
    • Topiramate tablets can become bitter once crushed5

  • Pill dysphagia can result in low adherence and treatment failure9*

*EPRONTIA™ does not have head-to-head data on adherence.

Important Safety Information (cont)

Metabolic Acidosis: Metabolic acidosis was commonly observed in adults and pediatric patients in clinical trials and is caused by renal bicarbonate loss due to carbonic anhydrase inhibition by topiramate. Conditions or therapies that predispose patients to acidosis (such as renal disease, severe respiratory disorders, status epilepticus, diarrhea, ketogenic diet, or specific drugs) may be additive to the bicarbonate lowering effects of topiramate. EPRONTIA treatment that causes metabolic acidosis during pregnancy can possibly produce adverse effects on the fetus and might also cause metabolic acidosis in the neonate from possible transfer of topiramate to the fetus. Baseline and periodic serum bicarbonate measurements are recommended during EPRONTIA treatment. If metabolic acidosis develops, consideration should be given to either dose reduction or discontinuation of therapy using dose tapering.

Please see additional Important Safety Information throughout, and the accompanying full Prescribing Information.